Format

Send to

Choose Destination
World J Gastroenterol. 2019 Aug 21;25(31):4414-4426. doi: 10.3748/wjg.v25.i31.4414.

Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: Prevalence, diagnosis and treatment.

Author information

1
Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo 05403-000, Brazil.
2
Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, United States, ali.rezaie@cshs.org.

Abstract

Inflammatory bowel diseases (IBD), Crohn`s disease and ulcerative colitis, are chronic conditions associated with high morbidity and healthcare costs. The natural history of IBD is variable and marked by alternating periods of flare and remission. Even though the use of newer therapeutic targets has been associated with higher rates of mucosal healing, a great proportion of IBD patients remain symptomatic despite effective control of inflammation. These symptoms may include but not limited to abdominal pain, dyspepsia, diarrhea, urgency, fecal incontinence, constipation or bloating. In this setting, commonly there is an overlap with gastrointestinal (GI) motility and absorptive disorders. Early recognition of these conditions greatly improves patient care and may decrease the risk of mistreatment. Therefore, in this review we describe the prevalence, diagnosis and treatment of GI motility and absorptive disorders that commonly affect patients with IBD.

KEYWORDS:

Chronic intestinal pseudo-obstruction; Crohn’s disease; Dyssynergic defecation; Fecal incontinence; Gastrointestinal motility and absorptive disorders; Inflammatory bowel diseases; Irritable bowel syndrome; Small intestinal bacterial overgrowth; Small intestinal fungal overgrowth; Ulcerative colitis

Conflict of interest statement

Conflict-of-interest statement: This review was conducted without any financial support. LLB and AQF report not relevant conflict of interest. AR has served as a speaker and consultant and has received research grants from Bausch Health. AR has equity in Gemelli Biotech. Cedars-Sinai Medical Center has a licensing agreement with Bausch Health and Gemelli Biotech. AR has served as consultant for GutHub.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center